BJMO - volume 19, issue 4, june 2025
W. Lybaert MD, T. Vandamme MD, PhD, L. Mariën MSc, J. Ibrahim PhD, O. Islam MD, S. Chhajlani MD, A. Florez Romero MD, C. De Weerdt MSc, K. Blockhuys MSc, L. Verbruggen PhD, S. Raats MSc, D. Van Genechten , H. Leupe MD, I. Borbath MD, PhD, C. Deroose MD, PhD
During the ENETS Conference, the long-awaited results of the phase 3 COMPETE trial were presented, with the comparison of [177Lu]Lu-edotreotide (Peptide Receptor Radionuclide Therapy = PRRT) vs. everolimus in patients with grade 1–2 gastroenteropancreatic neuroendocrine tumours (GEP NET): PRRT outperformed everolimus in terms of objective response rate and also progression-free survival. Also, an update of the phase 2 OCCLURANDOM trial showed the superiority of PRRT vs. sunitinib in a direct comparison between these two treatment modalities. Alpha-PRRT is advancing in the field of NET as a promising treatment option, with the ACTION-1 trial actively recruiting now in Belgium. NET-IMPRESS, a novel methylation-based assay to diagnose and monitor NET patients using liquid biopsies, was rewarded as the most promising basic research project during the conference and will be tested in broader patient populations. Also, the prominent presence of the patient organisations INCA/VZW NET & MEN at ENETS coincides with the rapidly growing field of treatment options in recent years for our patients with NET.
In this report, the most important headlines will be discussed, with comments on the clinical relevance of the different studies.
(BELG J MED ONCOL 2025;19(4):166–184)
Read moreBJMO - volume 19, issue 2, march 2025
W. Lybaert MD, L. Mariën MSc, O. Islam MD, S. Chhajlani MD, C. De Weerdt MSc, I. Nietvelt MSc, S. Raats MSc, L. Verbruggen PhD, T. Vandamme MD, PhD
During the ESMO Conference in Barcelona in 2024, two important phase 3 studies in the field of neuro-endocrine tumours (NET) that were presented earlier this year were updated and also published subsequently. The NETTER-2 trial is shifting [177Lu]Lu-DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) to the first-line treatment setting of patients with advanced, well-differentiated grade 2 and grade 3 gastro-enteropancreatic (GEP) NET; the CABINET trial is adding cabozantinib as targeted systemic therapy for previously treated, progressive advanced extrapancreatic and pancreatic NET.
In this report, these two practice-changing NET trials will be discussed in depth, with comments on the clinical relevance and the outstanding questions.
(BELG J MED ONCOL 2025;19(2):78–82)
Read moreBJMO - 2024, issue 4, june 2024
W. Lybaert MD, T. Vandamme MD, PhD, L. Mariën MSc, O. Islam MD, S. Chhajlani MD, C. De Weerdt MSc, I. Nietvelt MSc, M. Ulenaers MD, V. Casneuf MD, M. Maly MD, K. Geboes MD, D. Van Genechten , H. Leupe MD, C.M. Deroose MD, PhD
During the ENETS Conference, the NETTER-2 trial was again in the spotlight and is shifting [177Lu]Lu-DOTATATE PRRT to the first-line treatment setting of patients with advanced, well-differentiated grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumours (NET). Nuclear medicine treatment for NET is now intensively focusing on alpha-emitting peptide receptor radionuclide therapy (PRRT). Adding immunotherapy to angiogenesis inhibition for NET is again a disappointing story, and all eyes are now set on the CAR T-cell technology to stimulate anti-tumour immune responses. Delta-like ligand 3 is an inhibitory Notch ligand selectively and highly expressed on the cell surface of small cell lung cancer and neuroendocrine carcinoma, and appears to be a promising target for bispecific T-cell engager therapy. In this report, the most important headlines will be discussed, with comments on the clinical relevance of the different studies.
(BELG J MED ONCOL 2024;18(4):164–75)
Read moreBJMO - volume 17, issue 4, june 2023
W. Lybaert MD, T. Vandamme MD, PhD, L. Mariën MSc, O. Islam MD, S. Chhajlani MD, I. Van der Massen MSc, N. Ahmadi Bidakhvidi MD, C.M. Deroose MD, PhD
The 2023 edition of the European Neuroendocrine Tumour Society (ENETS) congress was held in Vienna between 22nd and 24th March. This article aims to provide an overview of the most remarkable findings and insights presented during this congress.
(BELG J MED ONCOL 2023;17(4):139–49)
Read moreBJMO - volume 16, issue 6, october 2022
W. Lybaert MD, T. Vandamme MD, PhD, L. Mariën MSc, O. Islam MD, I. Van der Massen MSc, I. Karfis MD, PhD, H. Eggers , M. Peeters MD, PhD
The first World NET Forum brought together leading scientists in the neuroendocrine tumour (NET) field to present their cutting-edge research to inspire other scientists and clinicians. This meeting focused mainly on models in NET research, NET tumour biology, as well as therapeutic and diagnostic advances. This article discusses some of the most relevant and promising studies.
(BELG J MED ONCOL 2022;16(6):310–22)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
